EGFR and non-small cell lung carcinoma: Guardant360 CDx test was FDA approved as a companion diagnostic for patients with EGFR-mutant NSCLC, with EGFR exon 20 insertion NSCLC and with KRAS G12C mutations NSCLC who may benefit from treatment with Osimertinib, Amivantamab and Sotorasib, respectively.